Rothschild & Co. Asset Management US Inc. trimmed its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 7.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 409,102 shares of the company’s stock after selling 33,265 shares during the quarter. Rothschild & Co. Asset Management US Inc. owned 0.83% of LivaNova worth $29,439,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also made changes to their positions in LIVN. Creative Financial Designs Inc. ADV purchased a new stake in shares of LivaNova during the first quarter worth about $29,000. Quadrant Capital Group LLC increased its position in shares of LivaNova by 1,744.8% during the first quarter. Quadrant Capital Group LLC now owns 535 shares of the company’s stock worth $50,000 after acquiring an additional 506 shares during the last quarter. Financial Gravity Wealth Inc. purchased a new stake in shares of LivaNova during the first quarter worth about $81,000. Quantamental Technologies LLC purchased a new stake in shares of LivaNova during the first quarter worth about $97,000. Finally, Nisa Investment Advisors LLC increased its position in shares of LivaNova by 8.9% during the second quarter. Nisa Investment Advisors LLC now owns 1,900 shares of the company’s stock worth $137,000 after acquiring an additional 155 shares during the last quarter. 83.95% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:LIVN traded up $0.92 during mid-day trading on Tuesday, reaching $77.92. The stock had a trading volume of 10,368 shares, compared to its average volume of 414,716. The stock has a market cap of $3.82 billion, a P/E ratio of 24.50, a price-to-earnings-growth ratio of 3.32 and a beta of 0.56. LivaNova PLC has a 1-year low of $64.80 and a 1-year high of $131.54. The business has a 50 day simple moving average of $73.56. The company has a quick ratio of 0.67, a current ratio of 0.95 and a debt-to-equity ratio of 0.15.
In other LivaNova news, CFO Thad Allen Huston sold 2,000 shares of LivaNova stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $75.00, for a total value of $150,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Damien Mcdonald sold 1,000 shares of LivaNova stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $72.60, for a total value of $72,600.00. The disclosure for this sale can be found here. Insiders sold 5,300 shares of company stock valued at $387,999 over the last quarter. Insiders own 0.41% of the company’s stock.
A number of analysts have recently issued reports on the company. Piper Jaffray Companies reaffirmed a “buy” rating on shares of LivaNova in a research report on Wednesday, July 31st. ValuEngine raised LivaNova from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. BTIG Research reaffirmed a “hold” rating on shares of LivaNova in a research report on Wednesday, July 31st. Needham & Company LLC set a $91.00 target price on LivaNova and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Finally, Zacks Investment Research upgraded LivaNova from a “sell” rating to a “hold” rating in a research note on Wednesday, July 3rd. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. LivaNova currently has a consensus rating of “Buy” and an average price target of $107.20.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.